SYDNEY--(BUSINESS WIRE)--Vermilion Software (‘Vermilion’), the leading global supplier of client reporting and communications software, is delighted to announce that its reporting suite has been selected by one of the largest investment managers in Australia, Challenger.
Vermilion Reporting Suite was selected by Challenger Limited following a rigorous market selection process. The Vermilion solution will primarily be used in delivering reporting to Challenger’s institutional client base.
David Mackaway, General Manager of Operations at Challenger: “Vermilion’s multi-tenanted approach will enhance our ability to deliver reporting for our boutique investment manager partners and our Life company. Having the capability to provide factsheets, questionnaire responses and client reports from a single platform is an attractive proposition.”
The implementation project is scheduled to commence during the summer.
Simon Cornwell, Global Sales and Marketing Director at Vermilion: “We are delighted to have been selected by Challenger. The ability to scale and deliver content in multiple outputs, including web, PDF, HTML and PowerPoint, is a compelling case for growing investment management firms with discerning clients.”
Challenger Limited is an ASX-listed investment management firm managing $57.4 billion in assets (as at 31 March 2016). The firm is focussed on providing Australians with financial security in retirement. It operates two core investment businesses, a fiduciary Funds Management division and an APRA-regulated Life division.
- ENDS -
Notes to Editors
About Vermilion Software
Vermilion Software is a leading global provider of client reporting technology and services to the asset management industry. The Vermilion solution is designed to deliver accurate, flexible, and scalable client reporting and communications, empowering client service professionals to deliver multilingual, graphical, marketing-quality reports that are created through an automated process. The firm has offices in London, Boston, Singapore and Sydney.